Espinoza Octavio
SEC CIK 1905248 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | CFO | 59.3K | $156.1K | $15.27M | 42 | 2022-11-09 | 2026-08-12 |
Most active insiders at LGND, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Espinoza Octavio | CFO | — | $13.03M |
| 2 | Reardon Andrew | CLO, Sec | — | $8.77M |
| 3 | Haas Jason | Dir | — | $3.74M |
| 4 | LAMATTINA JOHN L | Dir | — | $2.44M |
| 5 | Gray Nancy Ryan | Dir | — | $1.35M |
| 6 | Aryeh Jason | Dir | — | $1.25M |
| 7 | KOZARICH JOHN W | Dir | — | $1.20M |
| 8 | Sabba Stephen L | Dir | — | $1.16M |
| 9 | Zimmermann Martine | Dir | — | $342.0K |
| 10 | Davis Todd C | CEO, Dir | — | — |
Transactions 42
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-14 17:05 | 2026-08-12 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $56.91 | +31.6K | 59.3K | +114% | +$1.80M |
| DT | 2026-08-14 17:05 | 2026-08-12 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale+OE | $292.06 | -31.6K | 27.7K | -53% | -$9.24M |
| 2026-07-06 17:11 | 2026-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | J - Other | $160.71 | +17 | 27.7K | +0.1% | +$2,732 | |
| DM | 2026-05-28 19:43 | 2026-05-27 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $57.58 | +1,736 | 27.7K | +7% | +$100.0K |
| D | 2026-03-27 | 2026-03-02 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | A - Grant | $0.00 | +4,933 | 37.9K | +15% | $0 |
| D | 2026-03-13 | 2026-03-11 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $92.65 | +2,405 | 24.1K | +11% | +$222.8K |
| D | 2026-03-13 | 2026-03-11 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale+OE | $225.00 | -3,057 | 21.0K | -13% | -$687.8K |
| DM | 2026-03-06 | 2026-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale+OE | $205.83 | -13.4K | 27.5K | -33% | -$2.76M |
| DM | 2026-03-06 | 2026-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $63.49 | +2,073 | 35.1K | +6% | +$131.6K |
| M | 2026-02-18 | 2026-02-14+ | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $183.83 | -11.8K | 32.2K | -27% | -$2.16M |
| M | 2026-02-18 | 2026-02-14 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | A - Grant | $0.00 | +16.2K | 36.0K | +82% | $0 |
| 2026-01-06 | 2025-12-31 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | J - Other | $95.68 | +8 | 28.6K | +0.0% | +$765.44 | |
| DM | 2025-12-18 | 2025-12-16 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $69.00 | +2,381 | 27.4K | +9% | +$164.3K |
| 2025-12-16 | 2025-12-12 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale | $188.31 | -1,804 | 26.2K | -6% | -$339.7K | |
| 2025-12-09 | 2025-12-05 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $184.87 | -1,862 | 28.0K | -6% | -$344.2K | |
| 2025-07-02 | 2025-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | J - Other | $91.08 | +224 | 29.9K | +0.8% | +$20.4K | |
| M | 2025-05-13 | 2025-05-09 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | P - Purchase | $104.06 | +1,500 | 27.9K | +6% | +$156.1K |
| D | 2025-03-06 | 2025-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | A - Grant | $0.00 | +7,484 | 26.4K | +40% | $0 |
| D | 2025-03-06 | 2025-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale | $115.03 | -5,000 | 18.9K | -21% | -$575.1K |
| M | 2025-02-19 | 2025-02-14+ | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $120.00 | -9,587 | 23.3K | -29% | -$1.15M |
| M | 2025-02-19 | 2025-02-14 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | A - Grant | $0.00 | +12.8K | 30.7K | +72% | $0 |
| 2024-12-26 | 2024-12-23 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale | $116.37 | -2,104 | 20.6K | -9% | -$244.8K | |
| 2024-12-06 | 2024-12-05 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $123.51 | -1,859 | 22.8K | -8% | -$229.6K | |
| M | 2024-09-24 | 2024-09-20 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale | $103.94 | -1,275 | 25.4K | -5% | -$132.5K |
| DM | 2024-09-19 | 2024-09-17 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $79.63 | +1,486 | 25.8K | +6% | +$118.3K |
| DM | 2024-08-30 | 2024-08-28 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $66.52 | +753 | 23.9K | +3% | +$50.1K |
| 2024-07-02 | 2024-06-28 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | J - Other | $60.71 | +267 | 23.6K | +1% | +$16.2K | |
| DM | 2024-05-17 | 2024-05-15+ | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale+OE | $86.26 | -13.3K | 23.5K | -36% | -$1.15M |
| DM | 2024-05-17 | 2024-05-17 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $55.71 | +6,917 | 23.4K | +42% | +$385.3K |
| D | 2024-02-29 | 2024-02-28 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale+OE | $88.46 | -140 | 29.8K | -0.5% | -$12.4K |
| DM | 2024-02-29 | 2024-02-28 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | M - OptEx | $56.62 | +1,264 | 29.4K | +4% | +$71.6K |
| D | 2024-02-29 | 2024-02-27 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | A - Grant | $0.00 | +7,208 | 28.6K | +34% | $0 |
| 2024-02-16 | 2024-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $74.65 | -1,479 | 21.4K | -6% | -$110.4K | |
| 2023-12-06 | 2023-12-05 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $59.61 | -1,269 | 22.9K | -5% | -$75.6K | |
| 2023-10-03 | 2023-10-01 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $59.92 | -346 | 24.2K | -1% | -$20.7K | |
| 2023-07-10 | 2023-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | J - Other | $56.78 | +375 | 24.5K | +2% | +$21.3K | |
| D | 2023-02-27 | 2023-02-23 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | A - Grant | $0.00 | +6,046 | 24.1K | +33% | $0 |
| 2023-02-17 | 2023-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $72.98 | -849 | 18.1K | -4% | -$62.0K | |
| 2023-01-04 | 2022-12-30 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | J - Other | $56.78 | +275 | 18.9K | +1% | +$15.6K | |
| D | 2022-12-15 | 2022-12-13 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | A - Grant | $0.00 | +11.0K | 18.7K | +143% | $0 |
| 2022-12-01 | 2022-11-30 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | F - Tax | $72.90 | -1,187 | 7,670 | -13% | -$86.5K | |
| 2022-11-10 | 2022-11-09 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | CFO | S - Sale | $75.64 | -1,696 | 8,857 | -16% | -$128.3K |
Purchase Sale Sale after option exercise All abbreviations